Life-science research is producing images and structural data at a scale that would have been hard to imagine not long ago. AI-based protein structure prediction has made three-dimensional models available for an enormous range of proteins. Cryo-electron microscopy, advanced light microscopy and spatial biology methods generate rich, multidimensional datasets. Single-cell and multi-omics studies add layers of information about what is happening inside tissues. For anyone trying to explain biology, the raw material has never been more plentiful.
And yet the central communication problem has not gone away. A research team still has to decide what a finding means, which details matter, and how to show a process that unfolds across scales and over time. If anything, the flood of data has made those decisions harder. This piece looks at how the new tools are changing visualization work, why human scientific judgment remains at the center of it, and what research and communications teams can do to keep their visuals both compelling and honest.
From scarcity to abundance
For much of the history of molecular biology, visualization was limited by what was known. If the structure of a protein had not been solved, an illustrator might represent it as a simple blob or a schematic shape. Many textbook diagrams of cellular processes were necessarily approximate because the underlying structural detail simply was not available.
That has changed. Predicted and experimentally determined structures are now widely accessible through public databases. Imaging methods reveal the arrangement of molecules inside cells with increasing resolution. Computational tools can model how molecules might move and interact. The bottleneck has shifted from obtaining structural information to selecting, interpreting and presenting it.
That shift is changing the job of scientific visualization. It is less about filling gaps with educated guesses and more about curating a coherent story from an overwhelming amount of material, while being clear about which parts of that story rest on solid evidence and which are still uncertain.
What AI tools change, and what they do not
AI is now part of the visualization workflow in several ways. It helps predict structures, segment microscopy images, clean up noisy data and, increasingly, generate images and video from text prompts. Each of these has a different relationship to scientific accuracy.
Tools that work from data
Structure prediction and image analysis tools operate on scientific inputs and produce outputs that can, in principle, be checked. A predicted structure typically comes with confidence measures. A segmented image can be compared with the original. These tools are powerful aids to visualization because they give artists and scientists better starting material. But they still require interpretation. A predicted structure may be confident in one region and uncertain in another. A protein may adopt different shapes in different contexts. Someone has to decide which version to show and how to signal uncertainty.
Tools that generate imagery
Generative image and video models are a different matter. They produce plausible-looking pictures based on patterns in training data, not on the specific biology being described. A generated image of a “cell membrane receptor binding a drug” may look convincing to a lay viewer while being wrong in scale, structure and mechanism. For mood boards, early concept exploration or decorative backgrounds, such tools can save time. For any visual that claims to show how biology works, their output needs the same scientific scrutiny as any other illustration, and often more, because errors can be subtle and confidently rendered.
What stays the same
Regardless of the tools, the key questions in a visualization project remain human questions. What is the scientific claim? Which molecules, cells and tissues are essential to it? At what scale should each be shown? What is known, what is hypothesized, and what is simplified for clarity? These are judgments about meaning, and they depend on expertise and on the context in which the visual will be used.
Molecular visualization: choosing what to show
Molecular scenes are where the tension between abundance and clarity is most obvious. A realistic depiction of the inside of a cell is extraordinarily crowded. Showing every molecule at its true density would make most processes impossible to follow. Visualization teams make deliberate choices to keep the story readable:
- Representation style. The same protein can be shown as a surface, a ribbon diagram, a simplified shape or a cluster of atoms. Each emphasizes different features and suits different audiences.
- Density and context. Teams often thin out the surrounding environment, keeping just enough context to remind viewers that the cell is crowded without obscuring the event of interest.
- Time compression. Molecular events happen at speeds and in sequences that do not map neatly onto a viewer’s experience. Animations compress, slow down or reorder events for clarity, which should be done carefully and, where it matters, acknowledged.
- Color. Molecules do not have color in the everyday sense. Color is a coding system, and consistent, meaningful color choices help audiences track components across a sequence.
None of these choices is wrong in itself. The problem arises when they are made without thought, or when the simplifications end up implying something the science does not support.
Mechanism of disease: visualizing the story before the treatment
One area where visualization has grown in importance is the explanation of disease mechanisms. Before a company or research group can explain how a therapy is intended to work, audiences often need to understand what goes wrong in the disease in the first place: which pathway is disrupted, which cells are affected, how damage accumulates in tissue over time.
Mechanism of disease animations typically move across scales. They might begin at the level of an organ, zoom into a tissue, then into a cell, and finally into the molecular interaction at the heart of the pathology. Done well, this gives clinicians, investors, patients and internal teams a shared mental model. Done poorly, it can overstate certainty about mechanisms that are still debated in the literature.
That is why mechanism work tends to start with a careful review of the evidence. Teams map out which steps are well established, which are supported by emerging data, and which are hypotheses. The script and visuals then reflect those distinctions, sometimes through narration, sometimes through visual cues such as softer rendering for speculative elements.
The ethics of accuracy
Visuals are persuasive. People tend to remember images more readily than text, and a polished animation can carry an authority that a written hypothesis does not. That creates responsibilities that the life-science community has increasingly discussed.
- Do not show more certainty than exists. If the structure of a complex is predicted rather than experimentally determined, or a mechanism is still under investigation, the visual and its accompanying text should not present it as settled fact.
- Avoid implying outcomes. Showing diseased tissue returning to health after a therapeutic molecule binds its target can act as an efficacy claim, even if no words make one. In regulated contexts, such imagery needs the same scrutiny as written claims.
- Be honest about simplification. Simplifying is necessary. Hiding that one has simplified is the problem. A brief note or a line of narration can go a long way.
- Document sources. Keeping a record of which structures, papers and datasets informed a visual allows it to be checked and updated later.
- Label generated content appropriately. If AI-generated imagery is used, teams should consider whether audiences need to know, and should never pass off generated images as experimental data.
What research teams and communications teams should do
Visualization often sits awkwardly between departments. Scientists hold the knowledge. Communications and marketing teams hold the budget and the deadlines. Getting good results usually means bringing them together early.
For research teams
- Define the single most important message a visual needs to convey before discussing aesthetics.
- Share primary sources, structures and data with the visualization team, along with notes on uncertainty.
- Make time for review at the storyboard stage, when changes are easy, rather than only at the end.
- Flag which simplifications are acceptable and which would distort the science.
For communications and commercial teams
- Involve scientific and medical reviewers from the start, and budget for their time.
- Be cautious with generative AI imagery for anything that represents mechanism or data.
- Plan for multiple audiences. A visual for scientific peers will look different from one for investors or patients.
- Choose partners with a documented review process and scientific staff, not just strong portfolios.
Specialist studios have emerged to fill this gap between science and storytelling. Life Render, for instance, works with pharma and biotech companies on mechanism and scientific animation and begins its projects with a discovery and scientific review stage before moving to scripting and storyboarding. Whether a team works with an outside studio or builds capacity internally, the principle is the same: the science has to be settled before the rendering starts.
A quick checklist for any scientific visual
QuestionWhy it matters What is the one claim this visual supports?Keeps the piece focused and reviewable Which elements are experimentally established?Prevents overstating certainty What has been simplified, and is that acknowledged?Protects credibility with expert viewers Who reviewed the science, and when?Creates accountability and a record Was any imagery AI-generated?Ensures generated content is checked and labeled appropriately The judgment remains human
The new generation of tools is genuinely changing life-science visualization. Teams can start from better structural data, explore ideas faster and produce more ambitious visuals than before. But more data does not automatically mean better understanding. Someone still has to decide what the story is, what the evidence supports and how to show it without misleading. Those decisions remain the core of the work, and they are where research and communications teams should focus their attention.
Frequently Asked Questions
Can AI-generated images be used in scientific communication?
They can be useful for early concept work or decorative elements, but any image representing a biological mechanism or data should be reviewed by experts for accuracy and should never be presented as experimental results.
How should uncertainty be shown in a visualization?
Common approaches include narration or captions noting what is hypothesized, visual distinctions such as softer or semi-transparent rendering for speculative elements, and supporting references in accompanying materials.
What is the difference between mechanism of disease and mechanism of action visuals?
Mechanism of disease visuals explain what goes wrong in a condition. Mechanism of action visuals explain how a therapy is designed to act. The first often sets the stage for the second.
Who should sign off on a scientific animation?
Typically scientists or medical experts familiar with the evidence, plus regulatory or legal reviewers when the content will be used in a commercial or promotional setting.
